Related Experiment Video
Updated: Sep 26, 2026
Murine Intrapulmonary Tracheal Transplantation: A Model for Investigating Obliterative Airway Disease After Lung Transplantation
Published on: November 10, 2023
CTLA4Ig-gene transfection inhibits obliterative airway disease in rats
Yusuke Kita1, Kazuya Suzuki, Hiroshi Nogimura
1Department of Thoracic Surgery, Haibara General Hospital, Shizuoka, Japan. kita21@aqua.ocn.ne.jp
Background:
Obliterative airway disease (OAD) is a major cause of long-term morbidity following lung transplantation. Its pathologic characteristics are small-airway inflammation and occlusion by fibrous tissue. However, the pathogenesis is uncertain and therapy is ineffective. This study presents the effects of CTLA4Ig-gene therapy on OAD in heterotopically transplanted rat tracheal allografts.
Methods:
Dark Agouti (DA, RT1a) allografts and Lewis (LEW, RT1l) isografts were transplanted into Lewis recipients. The tracheal graft was transplanted heterotopically into the subcutaneous pocket into the back. Adenoviral vectors (1.0x10(9) pfu) containing the CTLA4Ig-gene (AdCTLA4Ig) or the LacZ-gene (AdLacZ) were injected into the tail vein immediately after grafting. Grafts were harvested and examined after more than 35 days for mononuclear cell infiltration development and lumen occlusion with fibrosis.
Results:
Fully allogenic DA tracheas, treated with AdCTLA4Ig had significantly lower pathologic scores and infiltrating scores than the control allografts. The pathologic findings of the grafts, treated with AdCTLA4Ig, were very similar to those of the syngeneic grafts. The animals experienced no adverse events during follow-up. No evidence of vector-mediated tissue damage was seen in any graft.
Conclusions:
Adenoviral vectors containing the CTLA4Ig-gene markedly inhibited the obliteration of the airway lumen. OAD may be associated with T-cell responses against graft tissue and alloimmune injury.
Insights
CTLA4Ig-gene therapy significantly reduced airway obliteration in lung transplant models. This gene therapy shows promise for treating obliterative airway disease (OAD) by targeting T-cell responses.
Area of Science:
- Transplantation immunology
- Gene therapy
- Respiratory disease
Background:
- Obliterative airway disease (OAD) is a significant complication after lung transplantation, characterized by airway inflammation and fibrosis.
- Current understanding of OAD pathogenesis is limited, and effective therapies are lacking.
- This study investigates the potential of CTLA4Ig-gene therapy to treat OAD.
Purpose of the Study:
- To evaluate the efficacy of CTLA4Ig-gene therapy in a rat tracheal allograft model of OAD.
- To assess the impact of CTLA4Ig-gene therapy on airway inflammation and fibrosis.
- To determine the safety profile of adenoviral vector-mediated CTLA4Ig gene delivery.
Main Methods:
- Heterotopic rat tracheal allografts (Dark Agouti to Lewis recipients) were used.
- Adenoviral vectors encoding CTLA4Ig (AdCTLA4Ig) or LacZ (AdLacZ) were administered intravenously post-transplantation.
- Grafts were analyzed after 35 days for pathological changes, including inflammation and lumen occlusion.
Main Results:
- AdCTLA4Ig treatment significantly reduced pathological scores and inflammatory cell infiltration compared to controls.
- Grafts treated with AdCTLA4Ig exhibited pathology similar to syngeneic grafts.
- No adverse events or vector-mediated tissue damage were observed.
Conclusions:
- Adenoviral vector-mediated CTLA4Ig-gene therapy effectively inhibits airway lumen obliteration in a preclinical model.
- OAD pathogenesis may involve T-cell mediated alloimmune injury.
- CTLA4Ig-gene therapy represents a potential therapeutic strategy for OAD.
